{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:01:41Z","timestamp":1768701701324,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s10549-022-06574-8","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T14:03:32Z","timestamp":1653746612000},"page":"337-351","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Racial disparities in neutrophil counts among patients with metastatic breast cancer during treatment with CDK4\/6 inhibitors"],"prefix":"10.1007","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4714-3661","authenticated-orcid":false,"given":"Ashley","family":"Schreier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Munoz-Arcos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus D.","family":"Anampa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,28]]},"reference":[{"issue":"7","key":"6574_CR1","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1021\/jm049354h","volume":"48","author":"PL Toogood","year":"2005","unstructured":"Toogood PL et al (2005) Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4\/6. J Med Chem 48(7):2388\u20132406","journal-title":"J Med Chem"},{"issue":"5","key":"6574_CR2","doi-asserted-by":"publisher","first-page":"R77","DOI":"10.1186\/bcr2419","volume":"11","author":"RS Finn","year":"2009","unstructured":"Finn RS et al (2009) PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 11(5):R77","journal-title":"Breast Cancer Res"},{"issue":"1","key":"6574_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS et al (2015) The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25\u201335","journal-title":"Lancet Oncol"},{"issue":"20","key":"6574_CR4","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS et al (2016) Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 375(20):1925\u20131936","journal-title":"N Engl J Med"},{"issue":"20","key":"6574_CR5","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC et al (2018) Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med 379(20):1926\u20131936","journal-title":"N Engl J Med"},{"issue":"32","key":"6574_CR6","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP et al (2017) MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 35(32):3638\u20133646","journal-title":"J Clin Oncol"},{"issue":"18","key":"6574_CR7","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN et al (2016) Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 375(18):1738\u20131748","journal-title":"N Engl J Med"},{"issue":"24","key":"6574_CR8","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ et al (2018) Phase III Randomized study of Ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth Factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 36(24):2465\u20132472","journal-title":"J Clin Oncol"},{"issue":"7","key":"6574_CR9","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D et al (2018) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 19(7):904\u2013915","journal-title":"Lancet Oncol"},{"issue":"17","key":"6574_CR10","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","volume":"23","author":"MN Dickler","year":"2017","unstructured":"Dickler MN et al (2017) MONARCH 1, A Phase II study of Abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)\/HER2(-) metastatic breast cancer. Clin Cancer Res 23(17):5218\u20135224","journal-title":"Clin Cancer Res"},{"issue":"25","key":"6574_CR11","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr et al (2017) MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 35(25):2875\u20132884","journal-title":"J Clin Oncol"},{"issue":"3","key":"6574_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC et al (2015) Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373(3):209\u2013219","journal-title":"N Engl J Med"},{"issue":"1","key":"6574_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13058-015-0661-5","volume":"18","author":"RS Finn","year":"2016","unstructured":"Finn RS, Aleshin A, Slamon DJ (2016) Targeting the cyclin-dependent kinases (CDK) 4\/6 in estrogen receptor-positive breast cancers. Breast Cancer Res 18(1):17","journal-title":"Breast Cancer Res"},{"key":"6574_CR14","doi-asserted-by":"publisher","first-page":"175883591879332","DOI":"10.1177\/1758835918793326","volume":"10","author":"M Thill","year":"2018","unstructured":"Thill M, Schmidt M (2018) Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol 10:1758835918793326","journal-title":"Ther Adv Med Oncol"},{"issue":"15","key":"6574_CR15","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1182\/blood-2018-08-872648","volume":"133","author":"IZ Uras","year":"2019","unstructured":"Uras IZ et al (2019) CDK6 coordinates JAK2 (V617F) mutant MPN via NF-\u03baB and apoptotic networks. Blood 133(15):1677\u20131690","journal-title":"Blood"},{"issue":"9","key":"6574_CR16","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1038\/sj.emboj.7601675","volume":"26","author":"T Fujimoto","year":"2007","unstructured":"Fujimoto T et al (2007) Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C\/EBPalpha interaction. Embo j 26(9):2361\u20132370","journal-title":"Embo j"},{"key":"6574_CR17","unstructured":"Maurer, B., et al., Inducible deletion of CDK4 and CDK6 - deciphering CDK4\/6 inhibitor effects in the hematopoietic system. Haematologica, 2020."},{"issue":"2","key":"6574_CR18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","volume":"64","author":"GP Bodey","year":"1966","unstructured":"Bodey GP et al (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64(2):328\u2013340","journal-title":"Ann Intern Med"},{"issue":"3","key":"6574_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-0609.1988.tb01192.x","volume":"41","author":"Y Shoenfeld","year":"1988","unstructured":"Shoenfeld Y et al (1988) Benign familial leukopenia and neutropenia in different ethnic groups. Eur J Haematol 41(3):273\u2013277","journal-title":"Eur J Haematol"},{"issue":"7","key":"6574_CR20","doi-asserted-by":"publisher","first-page":"486","DOI":"10.7326\/0003-4819-146-7-200704030-00004","volume":"146","author":"MM Hsieh","year":"2007","unstructured":"Hsieh MM et al (2007) Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med 146(7):486\u2013492","journal-title":"Ann Intern Med"},{"key":"6574_CR21","doi-asserted-by":"publisher","first-page":"579075","DOI":"10.3389\/fonc.2020.579075","volume":"10","author":"N Alpert","year":"2020","unstructured":"Alpert N et al (2020) Prevalence of cytopenia in the general population-a national health and nutrition examination survey analysis. Front Oncol 10:579075","journal-title":"Front Oncol"},{"issue":"10","key":"6574_CR22","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1200\/JCO.2009.24.3881","volume":"28","author":"MM Hsieh","year":"2010","unstructured":"Hsieh MM et al (2010) Neutrophil count in African Americans: lowering the target cutoff to initiate or resume chemotherapy? J Clin Oncol 28(10):1633\u20131637","journal-title":"J Clin Oncol"},{"issue":"1","key":"6574_CR23","doi-asserted-by":"publisher","first-page":"e1000360","DOI":"10.1371\/journal.pgen.1000360","volume":"5","author":"D Reich","year":"2009","unstructured":"Reich D et al (2009) Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS Genet 5(1):e1000360","journal-title":"PLoS Genet"},{"key":"6574_CR24","unstructured":"Services, U.D.o.H.a.H., CTCAE V5. 2017."},{"issue":"3","key":"6574_CR25","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3816\/CBC.2005.n.029","volume":"6","author":"K Smith","year":"2005","unstructured":"Smith K et al (2005) Ethnic disparities in adjuvant chemotherapy for breast cancer are not caused by excess toxicity in black patients. Clin Breast Cancer 6(3):260\u2013266","journal-title":"Clin Breast Cancer"},{"issue":"20","key":"6574_CR26","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1093\/jnci\/djg073","volume":"95","author":"D Hershman","year":"2003","unstructured":"Hershman D et al (2003) Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst 95(20):1545\u20131548","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"6574_CR27","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1200\/JCO.2008.19.1163","volume":"27","author":"D Hershman","year":"2009","unstructured":"Hershman D (2009) Treatment quality and outcomes of african american versus white breast cancer patients: retrospective analysis of southwest oncology studies S8814\/S8897. J Clin Oncol 27(13):2157\u20132162","journal-title":"J Clin Oncol"},{"issue":"3","key":"6574_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1001\/jamaoncol.2017.4658","volume":"4","author":"ME Vastola","year":"2018","unstructured":"Vastola ME et al (2018) Laboratory eligibility criteria as potential barriers to participation by black men in prostate cancer clinical trials. JAMA Oncol 4(3):413\u2013414","journal-title":"JAMA Oncol"},{"issue":"19","key":"6574_CR29","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1002\/cncr.33620","volume":"127","author":"F Lynce","year":"2021","unstructured":"Lynce F et al (2021) Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. Cancer 127(19):3622\u20133630","journal-title":"Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06574-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06574-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06574-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T18:35:37Z","timestamp":1656441337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06574-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,28]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["6574"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06574-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,28]]},"assertion":[{"value":"19 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of Montefiore Medical Center\/Einstein College of Medicine approved this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}